[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NIN Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100560387",false,"NCT06576479","Effect of a Specialized Oral Supplement on Nutritional Status and Quality of Life in Non-dialysis CKD","Validation of the Therapeutic Effect and Safety of a Specialized Oral Supplement on the Nutritional Status and Quality of Life in Patients with Chronic Kidney Disease Without Replacement Therapy: (Grade G3a, G3b, G4 and G5)","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients with diabetic kidney with eGFR \\\u003C60 ml \u002F min \u002F 1.73m2 and ≥15 ml \u002F min \u002F 1.73m2, (stage G3a, G3b and G4 respectively)\n* Patients with protein energy expenditure (defined by serum albumin \\\u003C 3.8 g\u002Fdl)\n* Patients with protein energy expenditure (defined by 24-hour recall less than a dietary protein intake \\\u003C0.6 g\u002Fkg\u002Fd or have a consumption \\\u003C25 kcal\u002Fkg\u002Fd\n* Patients who can read and write (or primary caregiver)\n* Domicile within the metropolitan area\n\nExclusion Criteria:\n\n* Previous hospitalizations in the last month\n* Patients with serious complications (chronic infection, septicemia, cancer, HIV, Alzheimer's, uncontrolled heart failure, liver failure, cerebrovascular syndrome, malabsorption syndrome, or allergy to any ingredient in the nutritional supplement)\n* Patients with actual consumption of food supplements and \u002F or keto analogues.\n\nElimination Criteria:\n\n* Failure to attend nutritional assessment and biochemical testing at baseline, 2 months, and end of the study.\n* Failure to take the supplement \\>10% (\\>12 failed doses).\n* Diagnosis of any comorbidity during the intervention period.\n* Initiation of replacement therapy.\n* Identification of adverse effects.\n* Withdrawal of voluntary participation by the patient.\n* Death.","ALL","18 Years","90 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients whit chronic kidney disease (CKD) there is a high prevalence of nutritional disorders and negative changes in body composition, which is strongly associated with an increased risk of morbidity and mortality.",[26,27],"Chronic Kidney Diseases","Protein-Energy Malnutrition",[29,30,31],"chronic kidney disease","PEW","nutrition","RECRUITING","2024-12-16",{"date":35,"type":36},"2024-12-18","ACTUAL",{"date":38,"type":36},"2018-07-10",{"date":40,"type":20},"2025-03",{"name":42,"class":43},"NIN Institute","INDUSTRY",""]